Breaking News Instant updates and real-time market news.

ILMN

Illumina

$131.87

-2.22 (-1.66%)

, RHHBY

Roche

$28.67

-0.337 (-1.16%)

09:40
11/21/16
11/21
09:40
11/21/16
09:40

Roche for Illumina, Twitter rumors discussed again by Betaville's Harrington

In a new interview with Tip TV Finance, Betaville's Ben Harrington discussed rumors that Illumina (ILMN) could be a takeover target, possibly for Roche (RHHBY). Roche is speculated to be considering a deal for Illumina, but an agreement has been "held up by price." In multiple previous interviews with Tip TV, Harrington has also discussed rumors that Roche was considering revisiting a bid for Illumina. Harrington also discussed rumors regarding a buyout of Twitter (TWTR) once again. Reference Link

ILMN

Illumina

$131.87

-2.22 (-1.66%)

RHHBY

Roche

$28.67

-0.337 (-1.16%)

TWTR

Twitter

  • 30

    Nov

ILMN Illumina
$131.87

-2.22 (-1.66%)

10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
11/02/16
FANA
11/02/16
DOWNGRADE
Target $116
FANA
Underweight
Illumina downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda downgraded Illumina to Underweight saying the valuation is too high given management's "unconvincing arguments about the outlook," his concerns regarding overcapacity and a "continued lack of new products in the near-term pipeline." The analyst lowered his price target for the shares to $116 from $130 following Illumina's Q3 results.
11/10/16
LEER
11/10/16
INITIATION
Target $145
LEER
Market Perform
Illumina resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of Illumina with a Market Perform rating and $145 price target.
RHHBY Roche
$28.67

-0.337 (-1.16%)

10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
TWTR Twitter

11/10/16
LOOP
11/10/16
NO CHANGE
Target $16
LOOP
Hold
Bain departure a loss for Twitter, says Loop Capital
Loop Capital analyst Blake Harper said the departure of COO Adam Bain is a loss for Twitter (TWTR), noting that he is well regarded internally and within the tech and advertising industries. Twitter is now searching for a full time CFO and a head of product and CEO Jack Dorsey continues to serve as full time CEO of Square (SQ) as well, which would "appear to leave its executive team stretched thin," said Harper, who keeps a Hold rating on Twitter shares.
11/10/16
LOOP
11/10/16
NO CHANGE
Target $151
LOOP
Buy
Netflix price target raised to $151 from $133 at Loop Capital
Loop Capital analyst David Miller raised his net subscriber growth assumptions for Netflix (NFLX) in 2017, taking up his domestic streaming net subscriber estimate by the end of 2017 to 53.7M from 53.6M and his end-year international net subscriber estimate to 55.8M from 54.8M. In doing so, he raised all of his income statement metrics and took up his price target accordingly to $151 from $133. Additionally, Miller contends that "simply because Twitter (TWTR) recently broadcast a few NFL games" does not mean Netflix will, or should, move into streaming sports.
10/28/16
10/28/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein saying the stock's valuation now "properly" reflects the challenging fundamental outlook. 2. Bristol-Myers (BMY) upgraded to Long-Term Buy from Neutral at Hilliard Lyons. 3. Qualcomm (QCOM) upgraded on valuation at BMO Capital with analyst Tim Long saying he is neutral on Qualcomm's acquisition of NXP (NXPI), but he expects Qualcomm's stock to stay in a trading range in the wake of the deal. 4. Level 3 (LVTL) upgraded to Outperform from Perform at Oppenheimer with analyst Timothy Horan saying the company has restructured itself in the last few years and now has operational/financial flexibility on free cash flow, with the analyst seeing accelerating growth in 2017. 5. ConocoPhillips (COP) upgraded to Overweight from Neutral at Piper Jaffray with analyst Guy Baber saying the company reported "another solid quarter." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/28/16
UBSW
10/28/16
NO CHANGE
Target $22
UBSW
Buy
Twitter shares continue to have compelling risk/reward, says UBS
UBS analyst Eric Sheridan said Twitter demonstrated stable to improving user growth and engagement for the second quarter in a row as its initiatives around live video and product begin to bear fruit. While investors continue to debate the company's stand alone vs. strategic value, Sheridan thinks the shares offer a compelling risk/reward. Sheridan reiterated his Buy rating and $22 price target on Twitter shares.

TODAY'S FREE FLY STORIES

VSAR

Versartis

$21.60

-0.25 (-1.14%)

17:00
09/21/17
09/21
17:00
09/21/17
17:00
Hot Stocks
Breaking Hot Stocks news story on Versartis 

Versartis trading resumes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLS

Flowserve

$42.19

-0.19 (-0.45%)

16:57
09/21/17
09/21
16:57
09/21/17
16:57
Hot Stocks
Flowserve appoints Lee Eckert as CFO »

Flowserve has named Lee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$60.50

0.38 (0.63%)

16:57
09/21/17
09/21
16:57
09/21/17
16:57
Periodicals
Regulators weigh removing SIFI 'tag' from insurer AIG, Dow Jones says »

According to the report,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$34.94

-0.06 (-0.17%)

16:54
09/21/17
09/21
16:54
09/21/17
16:54
Hot Stocks
Aecom announces capital allocation policy and $1B stock repurchase authorization »

Aecom announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$79.95

2.35 (3.03%)

16:49
09/21/17
09/21
16:49
09/21/17
16:49
Hot Stocks
Analogic achieves ECAC standard C2 for new cabin baggage screening solution »

Analogic announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$69.50

-0.45 (-0.64%)

16:39
09/21/17
09/21
16:39
09/21/17
16:39
Earnings
Compass Minerals lowers FY17 EPS view to $2.50-$2.80 from $3.00-$3.50 »

Consensus is $3.02. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 29

    Sep

MDU

MDU Resources

$26.21

-0.19 (-0.72%)

16:39
09/21/17
09/21
16:39
09/21/17
16:39
Hot Stocks
MDU Resources names Jason Vollmer CFO, Stephanie Barth CAO »

MDU Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:36
09/21/17
09/21
16:36
09/21/17
16:36
General news
Money Supply M2 Weekly Change data reported »

Week of 9/11 Money Supply…

16:36
09/21/17
09/21
16:36
09/21/17
16:36
General news
Fed Balance Sheet Level data reported »

Week of 9/20 Fed Balance…

TXN

Texas Instruments

$86.05

0.22 (0.26%)

16:35
09/21/17
09/21
16:35
09/21/17
16:35
Hot Stocks
Texas Instruments raises dividend 24%, adds to repurchase program »

Texas Instruments…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

16:34
09/21/17
09/21
16:34
09/21/17
16:34
Hot Stocks
Versartis' somavaratan did not meet primary endpoint in Phase 3 trial »

Versartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$90.44

-1.51 (-1.64%)

, DWDP

DowDuPont

$70.32

-0.09 (-0.13%)

16:34
09/21/17
09/21
16:34
09/21/17
16:34
Hot Stocks
FMC Corporation cleared for proposed acquisition of DuPont Crop Protection unit »

FMC Corporation (FMC)…

FMC

FMC Corporation

$90.44

-1.51 (-1.64%)

DWDP

DowDuPont

$70.32

-0.09 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MCD

McDonald's

$159.03

-0.85 (-0.53%)

16:32
09/21/17
09/21
16:32
09/21/17
16:32
Hot Stocks
McDonald's increases quarterly dividend 7% »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

16:30
09/21/17
09/21
16:30
09/21/17
16:30
Options
Preliminary option volume of 13.2M today »

Preliminary option volume…

TGI

Triumph Group

$27.85

-0.2 (-0.71%)

, BA

Boeing

$256.04

0.58 (0.23%)

16:27
09/21/17
09/21
16:27
09/21/17
16:27
Hot Stocks
Triumph Group signs contract extensions with Boeing for ducting, floor panels »

Triumph Group (TGI)…

TGI

Triumph Group

$27.85

-0.2 (-0.71%)

BA

Boeing

$256.04

0.58 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

16:25
09/21/17
09/21
16:25
09/21/17
16:25
Earnings
YogaWorks sees Q3 revenue $12.7M-$13.2M, consensus $12.9M »

For the third quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VSAR

Versartis

$21.60

-0.25 (-1.14%)

16:25
09/21/17
09/21
16:25
09/21/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Versartis »

Versartis trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

16:22
09/21/17
09/21
16:22
09/21/17
16:22
Earnings
YogaWorks reports Q2 adjusted net loss $3.1M vs. adjusted net loss $2.7M in Q216 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

CSII

Cardiovascular Systems

$27.63

0.38 (1.39%)

16:20
09/21/17
09/21
16:20
09/21/17
16:20
Initiation
Cardiovascular Systems initiated  »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
09/21/17
09/21
16:20
09/21/17
16:20
Options
Closing CBOE SPX and VIX Index summary for September 21st »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$11.45

0.01 (0.09%)

16:18
09/21/17
09/21
16:18
09/21/17
16:18
Syndicate
Breaking Syndicate news story on Immunomedics »

Immunomedics files 34.8M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNVR

Univar

$28.09

-0.11 (-0.39%)

16:17
09/21/17
09/21
16:17
09/21/17
16:17
Hot Stocks
Univar acquires Tagma Brasil »

Univar's wholly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
09/21/17
09/21
16:17
09/21/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPSN

LivePerson

$13.70

0.05 (0.37%)

16:17
09/21/17
09/21
16:17
09/21/17
16:17
Initiation
LivePerson initiated  »

LivePerson initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

PSDO

Presidio

$13.95

-0.06 (-0.43%)

16:16
09/21/17
09/21
16:16
09/21/17
16:16
Technical Analysis
Technical View: Presidio falls after results »

The company reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.